The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

GE Aerospace raised its full-year earnings outlook and beat expectations on its top and bottom lines in the second quarter. PepsiCo said its business remained resilient during the second quarter, ...

GE Aerospace raised its full-year earnings outlook and beat expectations on its top and bottom lines in the second quarter. PepsiCo said its business remained resilient during the second quarter, ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

New data from the VOLITION study reveal that 89% of treatment-naïve individuals with HIV chose to switch to long-acting cabotegravir and rilpivirine after achieving viral suppression with oral DTG/3TC ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

The global cardiac amyloidosis market is poised for substantial growth, driven by rising prevalence and awareness of amyloidosis-related cardiac cond ...

CenterBook Partners LP recently pared down its stake in Blackstone Inc. by 20.5%, selling 10,374 shares during the first ...